PENPenumbra, Inc.
$319.42+25% 1Y
$319.42
$225.5452 weeks$359.40
The financials
Penumbra, Inc. by the numbers
Penumbra, Inc. (PEN) reported revenue of $390M in Q2 2026 (quarter ended Jun 30, 2026), up 15% from the same quarter a year earlier. That came with a gross margin of 68% and net income of $35M (8.9% of revenue). For the full year FY2025, revenue was $1.40B (+17% year on year) and net income $178M. Its largest product in Q2 2026 was Thrombectomy at $259M, 66% of the disclosed total, well ahead of Embolization And Access at 34%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $390M | $339M | +15% |
| Gross profit | $265M | $224M | +18% |
| Operating income | $41M | $41M | +0.5% |
| Net income | $35M | $45M | −23% |
| Diluted EPS | $0.88 | $1.15 | −23% |
| Product | Revenue | Share |
|---|---|---|
| Thrombectomy | $259M | 66% |
| Embolization And Access | $131M | 34% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $390.0M (+4.1%)
Embolization And Access grew +20% year on yearThrombectomy +12% year on year
Segment Latestquarter on quarteryear on year
- Thrombectomy$259.0M$259.0Mquarter on quarter +2.0%year on year +12%+2.0%+12%
- Embolization And Access$131.1M$131.1Mquarter on quarter +8.5%year on year +20%+8.5%+20%